Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Status Completed

Clinical Trial Summary

Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of GC at the molecular level. This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of gastric cancer.Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal, immunogenic, metabolic, and classic.Our analysis has revealed that, for neoadjuvant therapy in advanced gastric cancer (AGC), the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib, without a concurrent increase in postoperative complications.

Clinical Trial Description

The advent of immunotherapy and targeted therapies has recently provided new options for AGC treatment. However, not all patients benefit from immunotherapy or targeted therapy, resulting in unsatisfactory overall treatment outcomes during the perioperative period. An ineffective treatment imposes significant financial burden, causes drug-related side effects that deteriorate their quality of life, and potentially delays subsequent treatment. Evaluate the objective response rate (ORR) of the combination of camrelizumb, apatinib, and neoadjuvant chemotherapy for the treatment of advanced gastric patient Median survival time (OS); Disease free survival time (DFS); ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06376773
Study type	Observational
Source	Fujian Medical University
Contact
Status	Completed
Phase
Start date	June 1, 2022
Completion date	November 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05161572` - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer	Phase 2
Not yet recruiting	`NCT05996484` - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma	Phase 2
Not yet recruiting	`NCT04520737` - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases	N/A
Recruiting	`NCT06138496` - Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC	Phase 2
Not yet recruiting	`NCT05983094` - Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer	Phase 2
Terminated	`NCT04440982` - Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients	Phase 2
Recruiting	`NCT04028375` - Study of CT and MR in the Gastric Cancer
Active, not recruiting	`NCT03192735` - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer	Phase 2
Recruiting	`NCT04588987` - Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma	Phase 2
Not yet recruiting	`NCT05993858` - Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC	Phase 2
Active, not recruiting	`NCT04666090` - Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT04848454` - Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy	Phase 2
Recruiting	`NCT04062058` - A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer	Phase 2
Recruiting	`NCT06124378` - Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer	Phase 2
Not yet recruiting	`NCT06125223` - PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
Recruiting	`NCT05371197` - Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer	Phase 2
Recruiting	`NCT06212440` - Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy	N/A
Completed	`NCT03178032` - Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas	Phase 1
Recruiting	`NCT02769104` - Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer	Phase 3
Active, not recruiting	`NCT04986306` - The Validation of Sentinel Lymph Node Biopsy After Neo-adjuvant Chemotherapy in Breast Cancer Patients